

Contact Information

BANTAM PHARMACEUTICAL
(704) 460-5330
www.bantampharma.com
mluther@bantampharma.com

Leadership Team

Mike Luther, PhD, MBA
Chief Executive Officer
Matt Kostura, PhD
Chief Scientific Officer
Alan Cooper, PhD
Head, Chemistry
Meghan Reynolds
Administrative Officer

Board of Directors

Mike Luther, PhD, MBA
Lionel Goldfrank
Victor Keen
John Reid
W. James Tozer Jr.

Scientific Advisors

Briggs Morrison, MD
Managing Partner MPM Capital,
CEO Syndax, Inc.
Mike Patane, PhD
Chief Scientific Officer,
Mitobridge, Inc.
Jedd Levine, MD, MBA
EVP Clinical Affairs, Oncology
Partners
Pam Cohen, MD
former Chief Medical Officer at
BluePrint Medicines, Novartis
Rainer Fuchs, PhD
former CIO Harvard Medical
School; Biogen & GSK R&D
George Mulligan, PhD
SVP Translational Medicine
Mitobridge, Inc.
Mark Manfredi, PhD
CSO Kyn Therapeutics, EIR Atlas
Ventures

Industry

Pharmaceuticals, Oncology
(Cancer metabolism, KRAS
mutated solid tumors /lymphoid
cancers)

Company Resources

Extensive IP estate with patent
protection through 2037

Type of Financing Sought

Development partnership



BANTAM PHARMACEUTICAL is an oncology therapeutics company with a novel pipeline of compounds that modulate cancer metabolism via ATF4 pathway. Bantam is targeting cancers of unmet need including refractive and resistant hematologic cancers and KRAS mutated solid tumors. Approvals in these areas would affect the lives of more than 150k patients/year in the US alone. With \$10 million in funding raised to date, Bantam Pharmaceutical is seeking partners and investors as it rapidly advances its pipeline toward clinical proof of concept studies.

ORGANIZATION: Bantam operates as a virtual company in a highly cost efficient manner. The leadership team members have proven track records in oncology biopharma drug discovery and development. Bantam's advisory board is comprised of prominent industry leaders with drug development and executive leadership roles with successful companies spanning start-up through global pharma.

SCIENCE AND PIPELINE: Using a structure-based drug design approach, Bantam has identified a unique set of compounds that repress tumor cell growth and increase overall survival in a diverse set of cancer cell types. The compounds are tumor specific and have no effect on normal cells. The compounds display exceptional *in vivo* activity in xenograft models including rapid and prolonged tumor regression in lymphoid xenografts, and potent activity against KRAS mutant solid tumors including, colorectal and lung cancers. The lead compounds possess excellent ADMET properties and are well tolerated *in vivo*.

The compounds modulate the ATF4 mediated Integrated Stress Response (ISR) pathway. Activation of ISR is primed by dysregulation of essential metabolic pathways resulting in upregulation of the tumor suppressors ATF4 and p21 that ultimately lead to cell cycle arrest at G0/G1 and apoptosis. Based on CRISPR, biochemical, genomic, and cell line profiling, Bantam has identified targets that are novel and distinct from other targeted therapeutics (e.g., histone deacetylase, proteasome, and kinase inhibitors including the cyclin-dependent kinase inhibitors).

ONCOLOGY – UNMET NEED AND IMPACT: Every year, more than 1.5 million people are diagnosed with cancer in the US, and almost 1,700 people die from this disease per day. Though survival rates as a whole have increased over the last decade, progress in therapeutic approaches has been incredibly variable, and for certain types of cancers, advances have been unsatisfactory. Bantam is committed to developing therapeutics that will address unmet needs in cancer with the following areas of focus:

Diffuse Large B-Cell Lymphoma (DLBCL): Diffuse Large B-Cell Lymphoma is a common form of non-Hodgkin's lymphoma and current standard of care is inadequate for about 50% of patients. Bantam's lead candidate induces apoptosis in a wide array of DLBCL cell lines including ABC and GCB subtypes as well as those characterized by Myc and Bcl-2 genomic alterations ("double-hit" lymphomas). These compounds induce rapid and sustained tumor regression in xenograft models of B-Cell Lymphoma. This opportunity represents a new therapeutic approach that may address the un/under-served patients with relapsed and refractory DLBCL.

KRAS Mutant Solid Tumors: Based on preclinical studies, KRAS mutated cancers are highly sensitivity to Bantam's compounds. KRAS is a frequent "driver" mutation of three of the four most lethal cancers, including colorectal cancer, lung adenocarcinoma, and pancreatic adenocarcinoma. The KRAS oncology segment represents a substantial unmet need for patients, which in the US is collectively >250k patients/year.

and/or capital investment of \$10,000,000

Total External Capital Invested
\$10,000,00 (from Founders and Investors)

Professionals

Jerry Silverman, CPA
Silverman Neu, LLP
Bill Gross, Esq.
Stearns, Weaver, Miller,
Weissler, Aldhadeff & Sitterson,
PA
Mike Rivard, TriUnity PLC
Shailesh Maingi, CEO Kineticos

Year Founded & Type of Entity
2015 Delaware LLC

Highlights

Bantam operates as a virtual company with a strong management team that has executive experience and expertise in oncology drug development from start-ups to global biopharma.

Demonstrated Proof of Concept in KRAS mutated solid tumor and as B-cell lymphoma xenograft studies. No significant adverse safety issues.

Initial studies published in *Bioorganic and Medicinal Chemistry Letters* and *AACR Proceedings*.

IP provides patent protection through 2037; Patent application publication: WO2016196644A1

Currently finalizing candidate selection studies for IND enabling GLP studies

Ongoing collaborations with McGill, NCI/NeXT, Frederick National Cancer Research Center, and SUNY-Hunter

INTELLECTUAL PROPERTY: Bantam owns an intellectual property estate that covers the compounds, associated chemical space and broad clinical utility. Bantam also owns recently filed patent applications that feature additional claims related to mechanism and all routes of administration. The IP portfolio will support Bantam’s pipeline and any derivative products through at least 2037.

NEAR TERM MILESTONES AND CLINIC PLANNING: Bantam is rapidly progressing its lead program into the clinic and is seeking funds to complete IND-enabling activities, manufacturing to support clinical trials, and Ph 1a/1b clinical studies.

| MILESTONES | |
|-------------------------------|---------|
| Candidate Selection | Q1 2018 |
| Initiate IND enabling studies | Q2 2018 |
| File IND | Q1 2019 |
| Initiate Phase Ib studies | Q2 2019 |
| Complete Phase Ib | Q4 2019 |

FUNDING STRATEGY AND USE OF PROCEEDS: Bantam has raised over \$5 million in three investor rounds post purchase of assets. The Company has achieved its stated milestones for each raise. Bantam is presently seeking funds and partnerships to: 1) initiate and complete CMC development, 2) progress the current candidate compound through IND-enabling studies, 3) Phase Ia/Ib clinical studies, and 4) bring the Company to an exit/partnering event with a significant investor ROI.